Nuovo Utente | Recupera PW

Dalla letteratura internazionale

• PLoS Med, 24 gennaio

  • Challenging Medical Ghostwriting in US Courts

• Lancet, 21 gennaio

  • Knowledge as a key resource for health challenges

• N Engl J Med, 19 gennaio

  • Generic Atorvastatin and Health Care Costs

• Ann Intern Med, 17 gennaio

  • Appropriate Use of Screening and Diagnostic Tests to Foster High-Value, Cost-Conscious Care

  • Exposing Unethical Human Research: The Transatlantic Correspondence of Beecher and Pappworth

  • High-Value Testing Begins With a Few Simple Questions 

• BMJ, 14 gennaio

  • Show us the data: why clinical outcomes matter
  • Patient reported outcome measures: how are we feeling today?
  • The idolatry of the surrogate
  • Why do single event probabilities confuse patients?

• JAMA, 11 gennaio

  • Addressing Requests by Patients for Nonbeneficial Interventions

• CMAJ, 10 gennaio

  • Early and continuing education: a prescription for achieving patient-centred care

• BMJ, 7 gennaio

  • Missing clinical trial data

  • Research misconduct in the UK

  • The NHS in England in 2012

  • Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses
  • Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis
  • Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study
  • Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey
  • Understanding why evidence from randomised clinical trials may not be retrieved from Medline: comparison of indexed and non-indexed records
  • Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications
  • Out of sight but not out of mind: how to search for unpublished clinical trial evidence
  • Managing research misconduct: is anyone getting it right?

• Lancet, 7 gennaio

  • Translational research and experimental medicine in 2012

  • Contracts with patients in clinical practice

• JAMA, 4 gennaio

  • Reversals of Established Medical Practices: Evidence to Abandon Ship

  • Where Are the Health Care Cost Savings?

  • International Variation in and Factors Associated With Hospital Readmission After Myocardial Infarction

• Ann Intern Med, 3 gennaio

  • Evaluation of Guideline Recommendations on Oral Medications for Type 2 Diabetes Mellitus: A Systematic Review

  • Distinguishing Case Series From Cohort Studies

  • Review of the American College of Physicians Ethics Manual, Sixth Edition

  • American College of Physicians Ethics Manual Sixth Edition

• N Engl J Med, 29 dicembre

  • The Savings Illusion — Why Clinical Quality Improvement Fails to Deliver Bottom-Line Results

• JAMA, 28 dicembre

  • Perceptions of Appropriateness of Care Among European and Israeli Intensive Care Unit Nurses and Physicians

  • Perceived Inappropriateness of Care in the ICU: What to Make of the Clinician’s Perspective?

• PLoS, 27 dicembre

  • Disclosure of Investigators' Recruitment Performance in Multicenter Clinical Trials: A Further Step for Research Transparency

• BMJ, 24 dicembre

  • Chistmas issue

• N Engl J Med, 22 dicembre

  • Implementation of the Federal Health Information Technology Initiative

• JAMA, 21 dicembre

  • Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs

  • Lessons From Recent Research About the Placebo Effect—From Art to Science

• Lancet, 17 dicembre

  • National disease registries for advancing health care

  • No evidence that patient choice in the NHS saves lives

• N Engl J Med, 15 dicembre

  • The Relationship between Hospital Admission Rates and Rehospitalizations

• CMAJ, 13 dicembre

  • Effectiveness of a quality-improvement program in improving management of primary care practices

  • Improving primary health care delivery: still waiting for the magic bullet

• PLoS Med, 13 dicembre

  • The Role of Group Dynamics in Scientific Inconsistencies: A Case Study of a Research Consortium

• BMJ, 10 dicembre

  • Honorary and ghost authorship
  • Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey
  • How clinical and research failures lead to suboptimal prescribing: the example of chronic gout
  • NICE’s recommendations for thromboembolism are not evidence based

• Lancet, 10 dicembre

  • Lessons from Lipitor and the broken blockbuster drug model

  • What constitutes full access to data in industry-funded trials?

  • Postgraduate medical education in England: 100 years of solitude

• N Engl J Med, 8 dicembre

  • Making Sense of the New Cervical-Cancer Screening Guidelines

  • Discussing Overall Prognosis with the Very Elderly

  • Learning about the Safety of Drugs — A Half-Century of Evolution

• PLoS, 6 dicembre

  • The Primacy of Public Health Considerations in Defining Poor Quality Medicines

• Lancet, 3 dicembre

  • Social accountability in health professionals’ training

• BMJ, 3 dicembre

  • Why do the results of randomised and observational studies differ?

  • New image for the drug industry
  • How attractive is the NHS to private providers?

• N Engl J med, 1 dicembre
  • The Four Habits of High-Value Health Care Organizations
  • Full Coverage for Preventive Medications after Myocardial Infarction
  • Improving Adherence — Money Isn't the Only Thing

• BMJ, 26 novembre

  • Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial
  • How evidence based is English public health policy?

• Lancet, 26 novembre

  • Evidence-based medicine comes to Gaza

• N Engl J Med, 24 novembre

  • Emergency Hospitalizations for Adverse Drug Events in Older Americans

• CMAJ, 22 novembre

  • Time to stop mammography screening?

• BMJ, 19 novembre

  • Ensuring quality in primary care

• Arch Intern Med, 14 novembre
  • Dramatic Increases in Carotid Stenting Despite Nonconclusive Data
  • Physician Specialty and Carotid Stenting Among Elderly Medicare Beneficiaries in the United States

• Lancet, 12 novembre

  • Reporting quality of life in clinical trials: a CONSORT extension

  • Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial

• BMJ, 12 novembre

  • Institutional research misconduct

  • Coping with scientific misconduct

• N Engl J Med, 10 novembre

  • Getting Moving on Patient Safety — Harnessing Electronic Data for Safer Care

  • Evidence-Based Medicine in the EMR Era

• JAMA, 9 novembre

  • Association Between Physician Billing and Cardiac Stress Testing Patterns Following Coronary Revascularization

  • Can the Patient-Centered Outcomes Research Institute Become Relevant to Controlling Medical Costs and Improving Value?

  • Narrative vs Evidence-Based Medicine—And, Not Or

  • Linking Insurance Coverage for Innovative Invasive Procedures With Participation in Clinical Research

  • Financial Incentives and the Art of Payment Reform

• BMJ, 5 novembre

  • Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? Yes

  • Should we use total mortality rather than cancer specific mortality to judge cancer screening programmes? No

  • Does competition between hospitals improve clinical quality? A review of evidence from two eras of competition in the English NHS

• New Engl J Med, 3 novembre

  • The Shortage of Essential Chemotherapy Drugs in the United States

• Ann Intern Med, 1 novembre

  • Evidence-Based Performance Measures: Preventing Unintended Consequences of Quality Measurement

• BMJ, 29 ottobre

  • Implementation of an electronic health record

  • Implementation and adoption of nationwide electronic health records in secondary care in England: final qualitative results from prospective national evaluation in “early adopter” hospitals

  • The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

• PLoS Med, 25 ottobre

  • STrengthening the Reporting of OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME): An Extension of the STROBE Statement

• Arch Intern Med, 24 ottobre

  • Why Is a Good Clinical Prediction Rule So Hard to Find?

  • Financial Payments by Orthopedic Device Makers to Orthopedic Surgeons

  • Industry Payments to Physicians

• BMJ, 22 ottobre

  • The Art of Risk Communication: What are natural frequencies?

  • Estimating treatment effects for individual patients based on the results of randomised clinical trials

• N Engl J Med, 20 ottobre

  • Defining Essential Health Benefits — The View from the IOM Committee

  • Medical Device Innovation — Is “Better” Good Enough?

• JAMA, 19 ottobre

  • Risk Prediction Models for Hospital Readmission: A Systematic Review

• Ann Intern Med, 18 ottobre

  • Interventions to Reduce 30-Day Rehospitalization: A Systematic Review

  • QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies

  • The Bedside Evaluation: Ritual and Reason

• BMJ, 15 ottobre

  • Conflicts of interest in guideline panel members

  • Letting the sunshine in on doctor-pharma relationships

  • Impact of CONSORT extension for cluster randomised trials on quality of reporting and study methodology: review of random sample of 300 trials, 2000-8

  • Speed of updating online evidence based point of care summaries: prospective cohort analysis

  • Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study

• N Engl J Med, 13 ottobre

  • The New Language of Medicine

  • The Patient-Centered Outcomes Research Institute — Promoting Better Information, Decisions, and Health

• JAMA, 12 ottobre

  • A Model for Dissemination and Independent Analysis of Industry Data

  • Improving the Food and Drug Administration's Mandate to Ensure Postmarketing Drug Safety

• Arch Intern Med, 10 ottobre

  • Defining "Appropriateness": The Devil Is in the Definition

  • Impact of National Clinical Guideline Recommendations for Revascularization of Persistently Occluded Infarct-Related Arteries on Clinical Practice in the United States

• BMJ, 8 ottobre

  • Teaching doctors in training about management and leadership

• JAMA, 5 ottobre

  • Quality Indicators for Older Adults: Preventing Unintended Harms

  • Time-Limited Trials Near the End of Life

• BMJ, 1 ottobre

  • Putting research into primary care practice

  • The politics of drug industry sponsorship

  • Funding grant proposals for scientific research: retrospective analysis of scores by members of grant review panel

  • How to obtain the confidence interval from a P value

• N Engl J Med, 29 settembre

  • Restrictions on the Use of Prescribing Data for Drug Promotion

• PLoS Med, 27 settembre

  • Why Drug Safety Should Not Take a Back Seat to Efficacy

• Arch Intern Med, 26 settembre

  • Too Little? Too Much? Primary Care Physicians' Views on US Health Care: A Brief Report

• BMJ, 24 settembre

  • Placebo by proxy

  • Breaking the rules: understanding non-compliance with policies and guidelines

• N Engl J Med, 22 settembre

  • Reforming the Regulations Governing Research with Human Subjects

• JAMA, 21 settembre

  • The FDA—A Misunderstood Agency

  • Evolving Research and Stakeholder Perspectives on Pharmacogenomics

  • Advancing Research Data Infrastructure for Patient-Centered Outcomes Research

• Ann Intern Med, 20 settembre

  • Providing High-Value, Cost-Conscious Care: A Critical Seventh General Competency for Physicians

• BMJ, 17 settembre

  • Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study

  • Statistics Notes

    • Correlation in restricted ranges of data

    • Statistics Notes: Brackets (parentheses) in formulas

• N Engl J Med, 15 settembre

  • Medical Devices — Balancing Regulation and Innovation

  • Medical Devices and Health — Creating a New Regulatory Framework for Moderate-Risk Devices

• Arch Intern Med, 12 settembre

  • Communicating Uncertainties About Prescription Drugs to the Public: A National Randomized Trial

  • Conservative Use of Prescription Drugs: Comment on "Communicating Uncertainties About Prescription Drugs to the Public"

  • Using Patients to Promote Evidence-Based Prescribing: Comment on "Communicating Uncertainties About Prescription Drugs to the Public"

  • Evidence Under Judgment: Can We Oversee Our Own Decision Making?

• BMJ, 10 settembre

  • Provision of health information for all

  • Evidence of comparative efficacy should have a formal role in European drug approvals

  • Target practice: choosing target conditions for test accuracy studies that are relevant to clinical practice

• JAMA, 7 settembre

  • Technology-Enhanced Simulation for Health Professions Education: A Systematic Review and Meta-analysis

  • Conflict of Interest Disclosure in Early Education of Medical Students

  • The Education and Training of Future Physicians: Why Coaches Can't Be Judges

• CMAJ, 6 settembre

  • The need for new mechanisms to ensure research integrity

  • Association of practice size and pay-for-performance incentives with the quality of diabetes management in primary care

  • Development of guidelines for recently arrived immigrants and refugees to Canada: Delphi consensus on selecting preventable and treatable conditions

  • Evaluation of evidence-based literature and formulation of recommendations for the clinical preventive guidelines for immigrants and refugees in Canada

• BMJ, 3 settembre

  • NIH updates its conflict of interest guidelines

  • Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study

  • Verification problems in diagnostic accuracy studies: consequences and solutions

• N Engl J Med, 1 settembre

  • The Art of Doing Nothing

• PLoS Med, 30 agosto

  • Ghostwriting Revisited: New Perspectives but Few Solutions in Sight

• JAMA, 24/31 agosto

  • Going Home on the Right Medications: Prescription Errors and Transitions of Care

• BMJ, 20 agosto

  • Surrogates under scrutiny: fallible correlations, fatal consequences

• N Engl J Med, 18 agosto

  • The Doctor's Dilemma — What Is “Appropriate” Care?

  • Malpractice Risk According to Physician Specialty

• JAMA, 17 agosto

  • Real-world Imperative of Outcomes Research

  • Implementing Accountable Care Organizations: Ten Potential Mistakes and How to Learn From Them

  • The Hazards of Evidence-Based Medicine: Assessing Variations in Care

• PLoS, 16 agosto

  • Building the Field of Health Policy and Systems Research: Framing the Questions

• Ann Intern Med, 16 agosto

  • Ethics and the Law: Is There Common Ground on Informed Consent for Disparities in Hospital Outcomes?

  • The Evolving Story of Guidelines and Health Care: Does Being NICE Help?

• BMJ, 13 agosto

  • Turning the tide on conflicts of interest

  • Disinvestment from low value clinical interventions: NICEly done?

• N Engl J Med, 11 agosto

  • History of Medicine: Combination Drugs — Hype, Harm, and Hope

• JAMA, 10 agosto

  • The Role of Physicians in Controlling Medical Care Costs and Reducing Waste

• PLoS, 9 agosto

  • Being the Ghost in the Machine: A Medical Ghostwriter's Personal View

  • How Industry Uses the ICMJE Guidelines to Manipulate Authorship—And How They Should Be Revised

• CMAJ, 9 agosto

  • Improving quality of care in nursing homes: What works?

  • Effects of multidisciplinary integrated care on quality of care in residential care facilities for elderly people: a cluster randomized trial

• Arch Intern Med, 8 agosto

  • The “Top 5” Lists in Primary Care

• Lancet, 6 agosto

  • What is the future of epidemiology?

  • Mathematical models in the evaluation of health programmes

  • Public health in England: an option for the way forward?

• BMJ, 6 agosto

  • Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

• Ann Intern Med, 2 agosto

  • Association of Hospitalist Care With Medical Utilization After Discharge: Evidence of Cost Shift From a Cohort Study

  • Moments in Time

• PLoS Med, 2 agosto

  • Reporting Guidelines for Survey Research: An Analysis of Published Guidance and Reporting Practices

  • Legal Remedies for Medical Ghostwriting: Imposing Fraud Liability on Guest Authors of Ghostwritten Articles

• BMJ, 30 luglio

  • WikiProject Medicine

• JAMA, 26 luglio

  • The Rational Clinical Examination. Does This Patient Have Medical Decision-Making Capacity?

  • Physician Stewardship of Health Care in an Era of Finite Resources

  • Evidence-Based Medicine in Surgery: The Importance of Both Experimental and Observational Study Designs

• Arch Intern Med, 25 luglio

  • Interventions to Decrease Hospital Readmission Rates: Who Saves? Who Pays?

  • The Care Transitions Intervention: Translating From Efficacy to Effectiveness

  • Effectiveness and Cost of a Transitional Care Program for Heart Failure: A Prospective Study With Concurrent Controls

  • Defining Health Information Technology–Related Errors: New Developments Since To Err Is Human

• BMJ, 23 luglio

  • Why patient safety is such a tough nut to crack

• Lancet, 23 luglio

  • Society’s failure to protect a precious resource: antibiotics

• JAMA, 20 luglio

  • Time to Take Health Delivery Research Seriously

• Ann Intern Med, 19 luglio

  • Communicating Data About the Benefits and Harms of Treatment: A Randomized Trial

• BMJ, 16 luglio

  • How to improve surgical research

  • Interpreting and reporting clinical trials with results of borderline significance

• CMAJ, 12 luglio

  • Can Health Canada protect Canadians from unsafe drugs?

• BMJ, 9 luglio

  • Patient information on prescribed drugs

  • Effect of financial incentives on incentivised and non-incentivised clinical activities: longitudinal analysis of data from the UK Quality and Outcomes Framework

• N Engl J Med, 7 luglio

  • Access to Safety Data — Stockholders versus Prescribers

  • New FDA Regulation to Improve Safety Reporting in Clinical Trials

  • Becoming a Physician: Level IV Evidence — Adverse Anecdote and Clinical Practice

  • Why Do the Same Drugs Look Different? Pills, Trade Dress, and Public Health

• JAMA, 6 luglio

  • Quality of Care and Patient Outcomes in Critical Access Rural Hospitals

  • Appropriateness of Percutaneous Coronary Intervention

  • Clinical Decision Support and Malpractice Risk

  • Application of Electronic Health Records to the Joint Commission's 2011 National Patient Safety Goals

• Ann Intern Med, 5 luglio

  • Single-Center Trials Show Larger Treatment Effects Than Multicenter Trials: Evidence From a Meta-epidemiologic Study

  • Metabias: A Challenge for Comparative Effectiveness Research

• BMJ, 2 luglio

  • The fraud squad

  • Skilled forensic capacity needed to investigate allegations of research misconduct

  • Why system inertia makes health reform so difficult

• N Engl J Med, 30 giugno

  • Comparative Effectiveness Research and Patients with Multiple Chronic Conditions

• JAMA, 22 giugno

  • Direct-to-Consumer Cardiac Screening and Suspect Risk Evaluation

  • Health Advocacy Organizations and Evidence-Based Medicine

• Ann Intern Med, 21 giugno

  • Enhancing Prescription Drug Innovation and Adoption

• BMJ, 18 giugno

  • Clinical trials: can technology solve the problem of low recruitment?

• CMAJ, 14 giugno

  • Industry’s neglect of prescribing information for children

• JAMA, 15 giugno

  • Surveillance Bias in Outcomes Reporting

• JAMA, 8 giugno

  • Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer

  • Balancing Access and Evaluation in the Approval of New Cancer Drugs

  • Realigning Incentives for Developing and Pricing New Anticancer Treatments

• Ann Intern Med, 7 giugno

  • A Summary of the Methods That the National Clinical Guideline Centre Uses to Produce Clinical Guidelines for the National Institute for Health and Clinical Excellence

  • National Clinical Guideline Centre Cost-Effectiveness Assessment for the National Institute for Health and Clinical Excellence

  • Trustworthy Clinical Guidelines 

• N Engl J Med, 2 giugno

  • Trends in Hospital Volume and Operative Mortality for High-Risk Surgery

• JAMA, 1 giugno

  • Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses

  • A New Frontier in Patient Safety

  • The Physics of Health Care Improvement

  • Comparative Effectiveness—Looking Under the Lamppost

  • The Thin Line Between Hope and Hype in Biomarker Research

• BMJ, 28 maggio

  • It’s time to rebuild the evidence base

  • Opening up data at the European Medicines Agency

  • EMA must improve the quality of its clinical trial reports

  • Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting

• N Engl J Med, 26 maggio

  • The $640 Billion Question — Why Does Cost-Effective Care Diffuse So Slowly?

  • Bending the Cost Curve in Cancer Care

• PLoS Med, 24 maggio

  • Medical Students' Exposure to and Attitudes about the Pharmaceutical Industry: A Systematic Review

• BMJ, 21 maggio

  • The regulation of medical devices

  • Medical devices

  • Medical device recalls and transparency in the UK

  • Inadequate reporting of research ethics review and informed consent in cluster randomised trials: review of random sample of published trials

• JAMA, 18 maggio

  • From Efficacy to Effectiveness in the Face of Uncertainty: Indication Creep and Prevention Creep

• Ann Intern Med, 17 maggio

  • Interpretation of Subgroup Analyses in Randomized Trials: Heterogeneity Versus Secondary Interventions

  • Select this articleMeaningful Use of Information Technology: A Local Perspective

  • Advancing the Science of Patient Safety

  • Select this articleThe Science of Safety Improvement: Learning While Doing

• CMAJ, 17 maggio

  • Sustainability is not the issue: Let’s focus on quality

• BMJ, 14 maggio

  • Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting

• Lancet, 14 maggio

  • Science as a public enterprise: the case for open data

  • Lancet UK Policy Matters: better evidence for better health

• JAMA, 11 maggio

  • Delivering Clinical Evidence Where It's Needed: Building an Information System Worthy of the Profession

• BMJ, 7 maggio

  • The true cost of pharmacological disease prevention

  • Reporting of eligibility criteria of randomised trials: cohort study comparing trial protocols with subsequent articles

• Lancet, 7 maggio

  • Value-based medicine pricing: NICE work?

  • Clinical research: time for sensible global guidelines

• N Engl J Med, 5 maggio

  • Statistics in Medicine: Pragmatic Trials — Guides to Better Patient Care?

• JAMA, 4 maggio

  • Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States 

  • Patient-Physican Communication: It's About Time

  • Would Accommodating Some Conscientious Objections by Physicians Promote Quality in Medical Care?

  • What Next for QALYs?

• PLoS, 3 maggio

  • Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview

• Ann Intern Med, 3 maggio

  • Individualized Guidelines: The Potential for Increasing Quality and Reducing Costs

  • Improving Practice Guidelines With Patient-Specific Recommendations

• Lancet, 30 aprile

  • Strengthening the regulation of herbal medicines in Europe

• BMJ, 30 aprile

  • Qualitative methods: an alternative view

  • Interpretation of random effects meta-analyses

• JAMA, 27 aprile

  • Association Between Adoption of Evidence-Based Treatment and Survival for Patients With ST-Elevation Myocardial Infarction

  • Implementation of Evidence-Based Therapies for Myocardial Infarction and Survival

• Arch Intern Med, 25 aprile

  • Personal Reflections on the High Cost of American Medical Care: Many Causes but Few Politically Sustainable Solutions

• Lancet. 23 aprile

  • Pay-for-performance and the Millennium Development Goals

  • A philosopher's view of the long road from RCTs to effectiveness

• BMJ, 23 aprile

  • Putting evidence into practice

  • Strategy for intention to treat analysis in randomised trials with missing outcome data

• N Engl J Med, 21 aprile

  • Launching Accountable Care Organizations — The Proposed Rule for the Medicare Shared Savings Program

  • New Directions in Medical Liability Reform

• JAMA, 20 aprile

  • Reforming the World Health Organization

  • How to Enroll Participants in Research Ethically

  • Health Services Research and Clinical Practice

  • Clinical Inertia as a Clinical Safeguard

• Ann Intern Med, 19 aprile

  • Professionalism in the Digital Age

• CMAJ, 19 aprile

  • How important is it to identify avoidable hospital readmissions with certainty?

  • Proportion of hospital readmissions deemed avoidable: a systematic review

• BMJ, 16 aprile

  • King’s Fund report on improving the quality of care in general practice

  • Who’s complacent now? The King’s Fund on general practice

• Lancet, 16 aprile

  • Medical errors in the USA: human or systemic?

• N Engl J Med, 14 aprile

  • How CER Could Pay for Itself — Insights from Vertebral Fracture Treatments

• N Engl J Med, 7 aprile

  • Determining the Value of Drugs — The Evolving British Experience

  • English NHS Embarks on Controversial and Risky Market-Style Reforms in Health Care

• JAMA, 7 aprile

  • A Potential Design Flaw of Randomized Trials of Vitamin Supplements

• PLoS, 5 aprile

  • Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints

• CMAJ, 5 aprile

  • A glimpse into the black box of cost-effectiveness analyses

  • Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test

  • New approaches to rewarding pharmaceutical innovation

• BMJ, 2 aprile

  • The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review

  • Strengths and weaknesses of hospital standardised mortality ratios

• Lancet, 2 aprile

  • Guiding the guidelines

  • Public reporting of surgical outcomes

• N Engl J Med, 31 marzo

  • Teaching Clinicians about Drugs — 50 Years Later, Whose Job Is It?

  • Becoming a Physician: Into the Water — The Clinical Clerkships

• PLoS Med, 29 marzo
  • On the Path to Global Open Access: A Few More Miles to Go
  • Towards Open and Equitable Access to Research and Knowledge for Development

• Arch Intern Med, 28 marzo
  • Better Off Not Knowing: Improving Clinical Care by Limiting Physician Access to Unsolicited Diagnostic Information
  • Not So Silver Lining
  • Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device Studies
  • The Persistent Exclusion of Older Patients From Ongoing Clinical Trials Regarding Heart Failure
  • Conflicts of Interest in Cardiovascular Clinical Practice Guidelines
  • Age-Based Exclusions From Cardiovascular Clinical Trials: Implications for Elderly Individuals (and for All of Us)
  • Can We Trust Cardiovascular Practice Guidelines?

• Lancet, 26 marzo

  • Key indicators of health in the USA

• BMJ, 26 marzo

  • Reducing unwarranted variations in healthcare in the English NHS

  • What have we learnt from the rosiglitazone saga?

  • New proposals for reorganisation of healthcare staff in England

  • Time to tackle unwarranted variations in practice

• N Engl J Med, 24 marzo

  • Early Accelerated Approval for Highly Targeted Cancer Drugs

  • Tapping the Unmet Potential of Health Information Technology

  • Specialization, Subspecialization, and Subsubspecialization in Internal Medicine

• JAMA, 23 marzo

  • In Search of Equipoise

  • A National Registry for Healthy Volunteers in Phase 1 Clinical Trials

• CMAJ, 22 marzo

  • Covert pharmaceutical promotion in free medical journals

  • A qualitative study of Canada’s experience with the implementation of electronic health information technology

  • The association between a journal’s source of revenue and the drug recommendations made in the articles it publishes

• BMJ, 19 marzo

  • Select this articleStrengthening the reporting of genetic risk prediction studies: the GRIPS statement

• JAMA, 16 marzo

  • Physician Communication in the 21st Century: To Talk or to Text?

  • Statistical Association and Causation: Contributions of Different Types of Evidence

• PLoS, 15 marzo

  • Strengthening the Reporting of Genetic Risk Prediction Studies: The GRIPS Statement

• BMJ, 12 marzo

  • Using bibliometrics to define the quality of primary care research

• JAMA, 9 marzo

  • Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments

• PLoS, 8 marzo

  • Predicting Harms and Benefits in Translational Trials: Ethics, Evidence, and Uncertainty

  • How Can Institutional Review Boards Best Interpret Preclinical Data?

• N Engl J Med, 3 marzo

  • Collaborative Clinical Trials

  • The ClinicalTrials.gov Results Database — Update and Key Issues

• JAMA, 2 marzo

  • Aligning Incentives for Academic Physicians to Improve Health Care Quality

  • The Need for Systems Integration in Health Care

• BMJ, 26 febbraio

  • Accessible medical research

  • Going local: devolving national pay for performance programmes

• N Engl J Med, 24 febbraio

  • Transforming Graduate Medical Education to Improve Health Care Value

  • Advancing Medical Education by Teaching Health Policy

• JAMA, 23 febbraio

  • Switching From Rosiglitazone: Thinking Outside the Class

  • Index Event Bias as an Explanation for the Paradoxes of Recurrence Risk Research

  • Direct-to-Consumer Advertising With Interactive Internet Media: Global Regulation and Public Health Issues

• PLos Med, 22 febbraio

  • Best Practice in Systematic Reviews: The Importance of Protocols and Registration

• BMJ, 19 febbraio

  • Cohort Studies: In for the long haul

  • The other Twitter revolution: how social media are helping to monitor the NHS reforms

  • Private finance initiatives during NHS austerity

• JAMA, 16 febbraio

  • Hospital Utilization and Characteristics of Patients Experiencing Recurrent Readmissions Within Children's Hospitals

  • Sudden Acceleration of Diabetes Quality Measures

  • How Many “Me-Too” Drugs Is Too Many?

  • A Historical Perspective on Clinical Trials Innovation and Leadership: Where Have the Academics Gone?

• Ann Intern Med, 15 febbraio

  • Exceptions to Outpatient Quality Measures for Coronary Artery Disease in Electronic Health Records

  • Measuring the Performance of Markers for Guiding Treatment Decisions

• Arch Intern Med, 14 febbraio

  • Future Directions in Industry Funding of Continuing Medical Education

• Lancet, 12 febbraio

  • Sharing research data to improve public health

  • European societies form biomedical alliance

• BMJ, 12 febbraio

  • Is quality of care improving in the UK?

  • Postmarketing studies of drug safety

  • Old drugs, new tricks

  • Research to decrease areas of clinical uncertainty

• N Engl J Med, 10 febbraio

  • Developing the Sentinel System — A National Resource for Evidence Development

  • Biomedical Research and Health Advances

  • The Role of Public-Sector Research in the Discovery of Drugs and Vaccines

• JAMA, 9 febbraio

  • The Clinical Research Enterprise: Time to Change Course?

• N Engl J Med, 3 febbraio

  • Equipoise and the Dilemma of Randomized Clinical Trials

• JAMA, 2 febbraio

  • Hospital Readmission as an Accountability Measure

• Lancet, 26 gennaio

  • The end of our National Health Service

• JAMA, 26 gennaio

  • A Multifaceted Intervention for Quality Improvement in a Network of Intensive Care Units: A Cluster Randomized Trial

  • The Promise of Comparative Effectiveness Research

  • Meaningful Disparities Reduction Through Research and Translation Programs

  • Improving the Science and Politics of Quality Improvement

• PLoS Med, 25 gennaio

  • Using the Delphi Technique to Determine Which Outcomes to Measure in Clinical Trials: Recommendations for the Future Based on a Systematic Review of Existing Studies

• BMJ, 22 gennaio

  • Assuring research integrity in the wake of Wakefield

  • Regulation and governance of clinical research in the UK

  • Have we gone too far in translating ideas from aviation to patient safety? Yes

  • Have we gone too far in translating ideas from aviation to patient safety? No

  • Secrets of the MMR scare: The Lancet’s two days to bury bad news

• Lancet, 22 gennaio

  • Checking for plagiarism, duplicate publication, and text recycling

• N Engl J Med, 20 gennaio

  • Broadening the Scope of Nursing Practice

• JAMA, 19 gennaio

  • Implications of the Principle of Question Propagation for Comparative-Effectiveness and “Data Mining” Research

  • Policy Options to Improve Discharge Planning and Reduce Rehospitalization

• Ann Intern Med, 18 gennaio

  • Addressing Missing Data in Clinical Trials

• Lancet, 15 gennaio

  • Untangling health research governance in the UK

  • A new era for UK clinical research?

• BMJ; 15 gennaio

  • Research into scorpion stings

  • Access to clinical trial data

  • Ensuring safe and effective drugs: who can do what it takes?

  • Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists

• CMAJ, 11 gennaio

  • Is bigger better? An argument for very low starting doses

• Arch Intern Med, 10 gennaio

  • Practice Guidelines: Belief, Criticism, and Probability

  • Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines

• BMJ, 8 gennaio

  • Wakefield’s article linking MMR vaccine and autism was fraudulent

• Lancet 8 gennaio

  • Where will new drugs come from?

  • An international registry of systematic-review protocols

• JAMA, 5 gennaio

  • Non–Evidence-Based ICD Implantations in the United States

  • Selecting Patients for ICD Implantation: Are Clinicians Choosing Appropriately?

• Ann Intern Med, 4 gennaio

  • A Systematic Examination of the Citation of Prior Research in Reports of Randomized, Controlled Trials